ES2711669A1 - Sistemas de liberacion de farmacos de acido polisialico y metodos - Google Patents

Sistemas de liberacion de farmacos de acido polisialico y metodos Download PDF

Info

Publication number
ES2711669A1
ES2711669A1 ES201731277A ES201731277A ES2711669A1 ES 2711669 A1 ES2711669 A1 ES 2711669A1 ES 201731277 A ES201731277 A ES 201731277A ES 201731277 A ES201731277 A ES 201731277A ES 2711669 A1 ES2711669 A1 ES 2711669A1
Authority
ES
Spain
Prior art keywords
composition according
polysialic acid
nanoentities
targeting group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES201731277A
Other languages
English (en)
Spanish (es)
Inventor
Fernandez Maria José Alonso
Osorio Desireé Teijeiro
Valino Carmen María Teijeiro
Pires Ana Cadete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to ES201731277A priority Critical patent/ES2711669A1/es
Priority to EP18808228.3A priority patent/EP3703666A1/en
Priority to PCT/EP2018/080050 priority patent/WO2019086627A1/en
Priority to AU2018361481A priority patent/AU2018361481B2/en
Priority to MX2020004639A priority patent/MX2020004639A/es
Priority to CA3079574A priority patent/CA3079574A1/en
Priority to JP2020524446A priority patent/JP7443230B2/ja
Priority to US16/760,527 priority patent/US20220071917A9/en
Publication of ES2711669A1 publication Critical patent/ES2711669A1/es
Priority to JP2024024604A priority patent/JP7756185B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES201731277A 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos Withdrawn ES2711669A1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES201731277A ES2711669A1 (es) 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos
EP18808228.3A EP3703666A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers
PCT/EP2018/080050 WO2019086627A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers
AU2018361481A AU2018361481B2 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers
MX2020004639A MX2020004639A (es) 2017-11-02 2018-11-02 Sistemas y metodos de administracion de farmacos que comprenden acido polisialico y/u otros polimeros.
CA3079574A CA3079574A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers
JP2020524446A JP7443230B2 (ja) 2017-11-02 2018-11-02 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
US16/760,527 US20220071917A9 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers
JP2024024604A JP7756185B2 (ja) 2017-11-02 2024-02-21 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201731277A ES2711669A1 (es) 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos

Publications (1)

Publication Number Publication Date
ES2711669A1 true ES2711669A1 (es) 2019-05-06

Family

ID=64477081

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201731277A Withdrawn ES2711669A1 (es) 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos

Country Status (8)

Country Link
US (1) US20220071917A9 (enExample)
EP (1) EP3703666A1 (enExample)
JP (2) JP7443230B2 (enExample)
AU (1) AU2018361481B2 (enExample)
CA (1) CA3079574A1 (enExample)
ES (1) ES2711669A1 (enExample)
MX (1) MX2020004639A (enExample)
WO (1) WO2019086627A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
AU2020266770A1 (en) 2019-05-01 2021-10-14 Universidade De Santiago De Compostela Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules
EP3986374B1 (en) * 2019-06-21 2026-01-28 Université catholique de Louvain Lipid nanocapsules charged with incretin mimetics
WO2021163097A1 (en) 2020-02-14 2021-08-19 Chang Gung Memorial Hospital Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
CN112048002B (zh) * 2020-08-07 2021-12-10 上海维洱生物医药科技有限公司 一种靶向t细胞的酶敏感纳米体系及其制备方法和应用
CN112402626B (zh) * 2020-11-26 2023-05-02 中国人民解放军陆军军医大学第二附属医院 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法
CA3221371A1 (en) * 2021-06-08 2022-12-15 Cytodigm, Inc. Novel particle composition comprising sialic acid binding ligand
CN115025241B (zh) * 2022-06-22 2023-08-01 西南民族大学 靶向cd22的纳米制剂及其制备方法和应用
WO2024118638A2 (en) * 2022-11-28 2024-06-06 Colorado School Of Mines Compositions and methods for making and using polymer-coated nanocapsules for targeted pharmaceutical agent delivery
WO2025085881A1 (en) 2023-10-20 2025-04-24 Eli Lilly And Company Nanoparticles and formulations thereof for delivering therapeutic agents throughout the central nervous system
EP4652991A1 (en) 2024-05-22 2025-11-26 Universidade de Santiago de Compostela Nanoassemblies for the intracellular delivery of active principles of aminoacidic nature
CN119318719B (zh) * 2024-09-24 2025-09-05 武汉理工大学 一种靶向神经氨酸酶的载药纳米粒及其制备方法和应用
CN119318718B (zh) * 2024-09-24 2025-10-03 武汉理工大学 一种pH/神经氨酸酶双响应载药纳米粒及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
ES2385995B2 (es) 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CA2825016C (en) 2011-01-24 2021-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
BR112014006596A2 (pt) 2011-09-21 2017-03-28 Yissum Res Dev Co nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US9993439B2 (en) * 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BADER, R.A. ET AL. Polysialic acid-based micelles for encapsulation of hydrophobic drugs. BIOMACROMOLECULES, 10/01/2011, Vol. 12, Páginas 314-320 (DOI: 10.1021/bm1008603) todo el documento.<br />BADER, R.A. ET AL. Polysialic acid-based micelles for encapsulation of hydrophobic drugs. BIOMACROMOLECULES, 10/01/2011, Vol. 12, Páginas 314-320 (DOI: 10.1021/bm1008603) todo el documento.<br /> *
ROTH, L. ET AL. Transtumoral targeting enabled by a novel neuropilin-binding peptide. ONCOGENE, 16/08/2012, Vol. 31, Páginas 3754-3763 (DOI: 10.10387onc.2011.537) todo el documento.<br /><br /> *
THWALA, L.N. ET AL. The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach. JOURNAL OF CONTROLLED RELEASE, 10/12/2016, Vol. 243, Páginas 109-120 (DOI: 10.1016/j.jconrel.2016.10.002) todo el documento.THWALA, L.N. ET AL. The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach. JOURNAL OF CONTROLLED RELEASE, 10/12/2016, Vol. 243, Páginas 109-120 (DOI: 10.1016/j.jconrel.2016.10.002) todo el documento. *

Also Published As

Publication number Publication date
MX2020004639A (es) 2020-11-06
US20210228494A1 (en) 2021-07-29
EP3703666A1 (en) 2020-09-09
AU2018361481B2 (en) 2024-06-13
JP2024059777A (ja) 2024-05-01
WO2019086627A1 (en) 2019-05-09
JP7443230B2 (ja) 2024-03-05
CA3079574A1 (en) 2019-05-29
US20220071917A9 (en) 2022-03-10
JP2021516211A (ja) 2021-07-01
JP7756185B2 (ja) 2025-10-17
AU2018361481A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7756185B2 (ja) ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
Koren et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity
Logie et al. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model
Shim et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
ES3042223T3 (en) Intracellular delivery of anti-kras antibodies formulated into nanocapsules
Chen et al. Progress in oncolytic viruses modified with nanomaterials for intravenous application
Yang et al. Bioresponsive chimaeric nanopolymersomes enable targeted and efficacious protein therapy for human lung cancers in vivo
Yang et al. A new concept of enhancing immuno-chemotherapeutic effects against B16F10 tumor via systemic administration by taking advantages of the limitation of EPR effect
Silvestre et al. Monoclonal antibodies carried in drug delivery nanosystems as a strategy for cancer treatment
Li et al. Recent advances in peptide-based therapeutic strategies for breast cancer treatment
Yang et al. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy
Peng et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy
CN110520109A (zh) 脂质体组合物及包含该组合物的固体口服剂型
Wu et al. Inflammation-targeted drug delivery strategies via albumin-based systems
Lee et al. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
Yan et al. Redox-responsive multifunctional polypeptides conjugated with Au nanoparticles for tumor-targeting gene therapy and their 1+ 1> 2 synergistic effects
CN102441175A (zh) 人血清白蛋白-siRNA纳米尺寸载体系统
Li et al. Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding
JP2018024590A (ja) 標的認識型組成物及びその用途
JP2024522316A (ja) 抗体がコンジュゲートされたリポソーム
Cheng et al. Fluorinated amphipathic cationic peptides for intracellular protein delivery and cancer immunotherapy
Huang Functionalized Lipid Nanoparticles Show Efficacy in Glioma Animal Models
Chang et al. Hao Wu1, 2, 3, Guoli Wei1, 2, 4, Lixia Luo1, 2, Lingchang Li1, 2, Yibo Gao1, 2, Xiaobin Tan1, 2, Sen Wang1, 2
WO2025037315A1 (en) Dendritic cells-targeted nanoparticles for t cell activation and cancer immunotherapy
Evans This chapter is a reprint of “Loujin Houdaihed, James C Evans, and Christine Allen. In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus. Cancers, 2019, 11 (6): 752.”

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2711669

Country of ref document: ES

Kind code of ref document: A1

Effective date: 20190506

FA2A Application withdrawn

Effective date: 20190923